News

Xilio's (XLO) Shares Surge 79.8% in a Month: Here's Why

Xilio (XLO) rallies 79.8% in a month on an exclusive global licensing agreement with Gilead Sciences to develop XTX301 for advanced solid tumors.

04/16/2024

Sizing Your Penny Stocks Position, 3 Tips

Sizing positions correctly is a cornerstone of successful investing, especially when dealing with penny stocks. The unique nature of penny stocks, with their potential for substantial gains, requires a nuanced approach to position sizing.

03/31/2024

Profitability

Dividends

Income Statement

Balance Sheet

Cash Flow Statement

Symbol Frequently Asked Questions

Is Xilio Therapeutics, Inc. (XLO) a buy, sell, or hold?

Xilio Therapeutics, Inc. (XLO) can sell. Click on Rating Page for detail.

What is Xilio Therapeutics, Inc.'s stock price?

The price of Xilio Therapeutics, Inc. (XLO) is 1.05 and it was updated on 2024-05-02 13:00:40.

Is Xilio Therapeutics, Inc. (XLO) overvalued or undervalued?

Currently Xilio Therapeutics, Inc. (XLO) is in undervalued.

News

From:

To:

News
Why Is Xilio Therapeutics (XLO) Stock up 168% Today? Xilio Therapeutics (NASDAQ: XLO ) stock is rocketing higher on Thursday after the clinical-stage biotechnology company signed an exclusive license agreement with Gilead Sciences (NASDAQ: GILD ). This agreement has Gilead taking over the development and commercialization responsibilities of Xilio Therapeutics' XTX301. Thu, Mar. 28, 2024
Xilio Therapeutics to Present at Guggenheim 6th Annual Biotechnology Conference WALTHAM, Mass., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that René Russo, Pharm.D., president and chief executive officer, will participate in a fireside chat at the Guggenheim 6th Annual Biotechnology Conference on Wednesday, February 7, 2024 at 12:30 pm EST. Wed, Jan. 31, 2024
Xilio to Host Virtual Investor Conference Call and Webcast on Monday, November 6, 2023 to Review Progress Across Pipeline, Including Phase 1/2 Clinical Data for XTX202, a Tumor-Activated, Engineered, Beta-Gamma IL-2, Presented at the SITC Annual Meeting WALTHAM, Mass., Oct. 31, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that it will host an investor conference call and webcast on November 6, 2023 at 8:00 a.m. ET to review progress across its pipeline of tumor-activated molecules, including Phase 1/2 clinical data for XTX202, an investigational tumor-activated, engineered, beta-gamma IL-2, which will be presented at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting, taking place in San Diego, California from November 1-5, 2023. Tue, Oct. 31, 2023
Xilio Therapeutics to Present at Morgan Stanley 21st Annual Global Healthcare Conference WALTHAM, Mass., Sept. 05, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a clinical-stage biotechnology company discovering and developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that René Russo, Pharm.D., chief executive officer, will participate in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference on Monday, September 11, 2023, at 2:55 pm EST. Tue, Sep. 05, 2023
Xilio Therapeutics to Present at Upcoming Investor Conferences WALTHAM, Mass., Feb. 27, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer, today announced its participation in the following upcoming investor conferences: Mon, Feb. 27, 2023

SEC Filings

SEC Filings
Xilio Therapeutics, Inc. (XLO) - S-3 SEC Filings 04/30/2024
Xilio Therapeutics, Inc. (XLO) - DEFA14A SEC Filings 04/25/2024
Xilio Therapeutics, Inc. (XLO) - DEF 14A SEC Filings 04/25/2024
Xilio Therapeutics, Inc. (XLO) - ARS SEC Filings 04/25/2024
Xilio Therapeutics, Inc. (XLO) - 424B5 SEC Filings 04/15/2024
Xilio Therapeutics, Inc. (XLO) - SC 13G/A SEC Filings 04/05/2024
Xilio Therapeutics, Inc. (XLO) - SC 13G SEC Filings 04/05/2024
Xilio Therapeutics, Inc. (XLO) - 4 SEC Filings 04/03/2024
Xilio Therapeutics, Inc. (XLO) - 3 SEC Filings 04/03/2024
Xilio Therapeutics, Inc. (XLO) - S-8 SEC Filings 04/01/2024
Xilio Therapeutics, Inc. (XLO) - 8-K - Current report SEC Filings 04/01/2024
Xilio Therapeutics, Inc. (XLO) - 10-K - Current report SEC Filings 04/01/2024
Xilio Therapeutics, Inc. (XLO) - 8-K - Current report SEC Filings 03/28/2024
Xilio Therapeutics, Inc. (XLO) - SC 13G SEC Filings 02/14/2024
Xilio Therapeutics, Inc. (XLO) - 4 SEC Filings 02/09/2024
Xilio Therapeutics, Inc. (XLO) - SC 13G/A SEC Filings 02/06/2024
Xilio Therapeutics, Inc. (XLO) - SC 13G/A SEC Filings 02/05/2024
Xilio Therapeutics, Inc. (XLO) - 8-K - Current report SEC Filings 01/19/2024
Xilio Therapeutics, Inc. (XLO) - 4 SEC Filings 01/16/2024
Xilio Therapeutics, Inc. (XLO) - 8-K - Current report SEC Filings 01/03/2024
Xilio Therapeutics, Inc. (XLO) - 4 SEC Filings 01/03/2024
Xilio Therapeutics, Inc. (XLO) - 8-K - Current report SEC Filings 12/07/2023
Xilio Therapeutics, Inc. (XLO) - 8-K - Current report SEC Filings 11/09/2023
Xilio Therapeutics, Inc. (XLO) - 10-Q/A - Quarterly Report SEC Filings 11/09/2023
Xilio Therapeutics, Inc. (XLO) - 10-Q - Quarterly Report SEC Filings 11/09/2023
Xilio Therapeutics, Inc. (XLO) - 10-K/A - Current report SEC Filings 11/09/2023
Xilio Therapeutics, Inc. (XLO) - 8-K - Current report SEC Filings 11/03/2023
Xilio Therapeutics, Inc. (XLO) - 4 SEC Filings 09/07/2023
Xilio Therapeutics, Inc. (XLO) - 3 SEC Filings 09/07/2023
Xilio Therapeutics, Inc. (XLO) - 8-K - Current report SEC Filings 09/05/2023
Xilio Therapeutics, Inc. (XLO) - 4 SEC Filings 08/18/2023
Xilio Therapeutics, Inc. (XLO) - 8-K - Current report SEC Filings 08/14/2023
Xilio Therapeutics, Inc. (XLO) - 10-Q - Quarterly Report SEC Filings 08/14/2023
Xilio Therapeutics, Inc. (XLO) - 4 SEC Filings 08/07/2023
Xilio Therapeutics, Inc. (XLO) - 3 SEC Filings 08/07/2023
Xilio Therapeutics, Inc. (XLO) - 8-K - Current report SEC Filings 08/03/2023
Xilio Therapeutics, Inc. (XLO) - 8-K - Current report SEC Filings 06/13/2023
Xilio Therapeutics, Inc. (XLO) - 4 SEC Filings 06/13/2023
Xilio Therapeutics, Inc. (XLO) - 8-K - Current report SEC Filings 05/25/2023
Xilio Therapeutics, Inc. (XLO) - 8-K - Current report SEC Filings 05/09/2023
Xilio Therapeutics, Inc. (XLO) - 10-Q - Quarterly Report SEC Filings 05/09/2023
Xilio Therapeutics, Inc. (XLO) - DEFA14A SEC Filings 04/25/2023
Xilio Therapeutics, Inc. (XLO) - DEF 14A SEC Filings 04/25/2023
Xilio Therapeutics, Inc. (XLO) - ARS SEC Filings 04/25/2023
Xilio Therapeutics, Inc. (XLO) - SC 13G SEC Filings 04/10/2023
Xilio Therapeutics, Inc. (XLO) - 8-K - Current report SEC Filings 04/03/2023
Xilio Therapeutics, Inc. (XLO) - 4 SEC Filings 04/03/2023
Xilio Therapeutics, Inc. (XLO) - 3 SEC Filings 04/03/2023
Xilio Therapeutics, Inc. (XLO) - S-8 SEC Filings 03/02/2023
Xilio Therapeutics, Inc. (XLO) - 8-K - Current report SEC Filings 03/02/2023
Xilio Therapeutics, Inc. (XLO) - 10-K - Current report SEC Filings 03/02/2023
Xilio Therapeutics, Inc. (XLO) - SC 13G/A SEC Filings 02/09/2023
Xilio Therapeutics, Inc. (XLO) - SC 13G SEC Filings 01/25/2023
Xilio Therapeutics, Inc. (XLO) - 8-K - Current report SEC Filings 01/09/2023
Xilio Therapeutics, Inc. (XLO) - 4 SEC Filings 01/04/2023
Xilio Therapeutics, Inc. (XLO) - SC 13G/A SEC Filings 12/29/2022
Xilio Therapeutics, Inc. (XLO) - 8-K - Current report SEC Filings 12/23/2022
Xilio Therapeutics, Inc. (XLO) - EFFECT SEC Filings 11/21/2022
Xilio Therapeutics, Inc. (XLO) - EFFECT SEC Filings 11/21/2022
Xilio Therapeutics, Inc. (XLO) - 3 SEC Filings 11/16/2022
Xilio Therapeutics, Inc. (XLO) - SC 13G/A SEC Filings 11/14/2022
Xilio Therapeutics, Inc. (XLO) - S-3 SEC Filings 11/09/2022
Xilio Therapeutics, Inc. (XLO) - 8-K - Current report SEC Filings 11/09/2022
Xilio Therapeutics, Inc. (XLO) - 10-Q - Quarterly Report SEC Filings 11/09/2022
Xilio Therapeutics, Inc. (XLO) - 4 SEC Filings 09/16/2022
Xilio Therapeutics, Inc. (XLO) - 8-K - Current report SEC Filings 09/15/2022
Xilio Therapeutics, Inc. (XLO) - 8-K - Current report SEC Filings 08/09/2022
Xilio Therapeutics, Inc. (XLO) - 10-Q - Quarterly Report SEC Filings 08/09/2022
Xilio Therapeutics, Inc. (XLO) - 8-K - Current report SEC Filings 07/28/2022
Xilio Therapeutics, Inc. (XLO) - 4/A SEC Filings 06/23/2022
Xilio Therapeutics, Inc. (XLO) - 4 SEC Filings 06/17/2022
Xilio Therapeutics, Inc. (XLO) - 3 SEC Filings 06/17/2022
Xilio Therapeutics, Inc. (XLO) - 8-K - Current report SEC Filings 06/16/2022
Xilio Therapeutics, Inc. (XLO) - 8-K - Current report SEC Filings 06/13/2022
Xilio Therapeutics, Inc. (XLO) - 8-K - Current report SEC Filings 05/12/2022
Xilio Therapeutics, Inc. (XLO) - 10-Q - Quarterly Report SEC Filings 05/12/2022
Xilio Therapeutics, Inc. (XLO) - DEFA14A SEC Filings 04/26/2022
Xilio Therapeutics, Inc. (XLO) - DEF 14A SEC Filings 04/26/2022
Xilio Therapeutics, Inc. (XLO) - S-8 SEC Filings 03/01/2022
Xilio Therapeutics, Inc. (XLO) - 8-K - Current report SEC Filings 03/01/2022
Xilio Therapeutics, Inc. (XLO) - 10-K - Current report SEC Filings 03/01/2022
Xilio Therapeutics, Inc. (XLO) - 4 SEC Filings 02/24/2022
Xilio Therapeutics, Inc. (XLO) - SC 13G/A SEC Filings 02/14/2022
Xilio Therapeutics, Inc. (XLO) - SC 13G/A SEC Filings 02/11/2022
Xilio Therapeutics, Inc. (XLO) - SC 13G/A SEC Filings 02/09/2022
Xilio Therapeutics, Inc. (XLO) - 8-K - Current report SEC Filings 02/04/2022
Xilio Therapeutics, Inc. (XLO) - SC 13G SEC Filings 01/14/2022
Xilio Therapeutics, Inc. (XLO) - 8-K - Current report SEC Filings 01/06/2022
Xilio Therapeutics, Inc. (XLO) - 4 SEC Filings 01/06/2022
Xilio Therapeutics, Inc. (XLO) - 3 SEC Filings 01/06/2022
Xilio Therapeutics, Inc. (XLO) - 4/A SEC Filings 01/04/2022
Xilio Therapeutics, Inc. (XLO) - 4 SEC Filings 12/23/2021
Xilio Therapeutics, Inc. (XLO) - 4 SEC Filings 12/10/2021
Xilio Therapeutics, Inc. (XLO) - 8-K - Current report SEC Filings 12/02/2021
Xilio Therapeutics, Inc. (XLO) - 10-Q - Quarterly Report SEC Filings 12/02/2021
Xilio Therapeutics, Inc. (XLO) - SC 13G SEC Filings 11/05/2021
Xilio Therapeutics, Inc. (XLO) - SC 13D SEC Filings 11/05/2021
Xilio Therapeutics, Inc. (XLO) - 3 SEC Filings 11/05/2021
Xilio Therapeutics, Inc. (XLO) - SC 13G SEC Filings 11/04/2021
Xilio Therapeutics, Inc. (XLO) - SC 13D SEC Filings 11/03/2021
Xilio Therapeutics, Inc. (XLO) - 4/A SEC Filings 11/03/2021
Xilio Therapeutics, Inc. (XLO) - 4 SEC Filings 10/28/2021
Xilio Therapeutics, Inc. (XLO) - SC 13G SEC Filings 10/27/2021
Xilio Therapeutics, Inc. (XLO) - 8-K - Current report SEC Filings 10/26/2021
Xilio Therapeutics, Inc. (XLO) - 4 SEC Filings 10/26/2021
Xilio Therapeutics, Inc. (XLO) - S-8 SEC Filings 10/25/2021
Xilio Therapeutics, Inc. (XLO) - 4 SEC Filings 10/25/2021
Xilio Therapeutics, Inc. (XLO) - EFFECT SEC Filings 10/22/2021
Xilio Therapeutics, Inc. (XLO) - SEC STAFF LETTER SEC Filings 10/22/2021
Xilio Therapeutics, Inc. (XLO) - S-8 SEC Filings 10/22/2021
Xilio Therapeutics, Inc. (XLO) - EFFECT SEC Filings 10/22/2021
Xilio Therapeutics, Inc. (XLO) - 424B4 SEC Filings 10/22/2021
Xilio Therapeutics, Inc. (XLO) - 3 SEC Filings 10/22/2021
Xilio Therapeutics, Inc. (XLO) - CERT SEC Filings 10/21/2021
Xilio Therapeutics, Inc. (XLO) - 3 SEC Filings 10/21/2021
Xilio Therapeutics, Inc. (XLO) - S-1/A SEC Filings 10/20/2021
Xilio Therapeutics, Inc. (XLO) - S-1/A SEC Filings 10/19/2021
Xilio Therapeutics, Inc. (XLO) - CORRESP SEC Filings 10/19/2021
Xilio Therapeutics, Inc. (XLO) - S-1/A SEC Filings 10/18/2021
Xilio Therapeutics, Inc. (XLO) - CORRESP SEC Filings 10/18/2021
Xilio Therapeutics, Inc. (XLO) - 8-A12B SEC Filings 10/18/2021
Xilio Therapeutics, Inc. (XLO) - UPLOAD SEC Filings 10/13/2021
Xilio Therapeutics, Inc. (XLO) - S-1 SEC Filings 10/01/2021
Xilio Therapeutics, Inc. (XLO) - CORRESP SEC Filings 10/01/2021
Xilio Therapeutics, Inc. (XLO) - UPLOAD SEC Filings 09/23/2021
Xilio Therapeutics, Inc. (XLO) - DRSLTR SEC Filings 09/14/2021
Xilio Therapeutics, Inc. (XLO) - DRS/A SEC Filings 09/14/2021
Xilio Therapeutics, Inc. (XLO) - SEC STAFF LETTER SEC Filings 06/25/2021
Xilio Therapeutics, Inc. (XLO) - UPLOAD SEC Filings 06/21/2021
Xilio Therapeutics, Inc. (XLO) - DRS SEC Filings 05/24/2021
Xilio Therapeutics, Inc. (XLO) - D SEC Filings 02/26/2021
Xilio Therapeutics, Inc. (XLO) - D SEC Filings 01/21/2021

Press Releases

StockPrice Release
Xilio therapeutics announces pipeline and business updates and fourth quarter and full year 2023 financial results 04/01/2024
Xilio therapeutics announces $11.3 million private placement equity financing 03/28/2024
Gilead and xilio announce exclusive license agreement for tumor-activated il-12 program 03/28/2024
Xilio therapeutics to participate in novel immuno-oncology panel at td cowen 44th annual health care conference 02/28/2024
Xilio therapeutics to present at guggenheim 6th annual biotechnology conference 01/31/2024
Xilio therapeutics highlights recent advances across clinical pipeline and encouraging preliminary phase 1 safety data for xtx301, a tumor-activated il-12, further validating the promise of its tumor-activated immuno-oncology therapies 01/08/2024
Xilio therapeutics announces initiation of enrollment for phase 1 combination trial of xtx101, a tumor-activated, fc-enhanced anti-ctla-4, and updated phase 1 monotherapy data 12/07/2023
Xilio therapeutics announces pipeline and business updates and third quarter 2023 financial results 11/09/2023
Xilio announces initial monotherapy safety and anti-tumor activity data for xtx202, a tumor-activated, engineered, beta-gamma il-2, in late line patients with advanced solid tumors 11/03/2023
Xilio to host virtual investor conference call and webcast on monday, november 6, 2023 to review progress across pipeline, including phase 1/2 clinical data for xtx202, a tumor-activated, engineered, beta-gamma il-2, presented at the sitc annual meeting 10/31/2023
Xilio therapeutics announces upcoming presentations at the society for immunotherapy of cancer's (sitc) 38th annual meeting 09/27/2023
Xilio therapeutics announces promotion of katarina luptakova, m.d., to chief medical officer and scott coleman, ph.d. 09/05/2023
Xilio therapeutics to present at morgan stanley 21st annual global healthcare conference 09/05/2023
Xilio therapeutics announces pipeline and business updates and second quarter 2023 financial results 08/14/2023
Xilio therapeutics announces promotion of chris frankenfield to chief operating officer 08/03/2023
Xilio therapeutics announces preliminary clinical data from phase 1 trial of xtx101, a tumor-activated, fc-enhanced anti-ctla-4, in patients with advanced solid tumors 05/25/2023
Xilio therapeutics announces pipeline and business updates and first quarter 2023 financial results 05/09/2023
Xilio therapeutics announces inducement grant under nasdaq listing rule 5635(c)(4) 04/03/2023
Xilio therapeutics announces pipeline and business updates for the fourth quarter and full year 2022 financial results 03/02/2023
Xilio therapeutics to present at upcoming investor conferences 02/27/2023
Xilio therapeutics to present at the citi 2023 virtual oncology leadership summit 02/16/2023
Xilio therapeutics to present at the guggenheim healthcare talks oncology day 02/02/2023
Xilio therapeutics to host live virtual program spotlighting xtx301, a tumor-activated il-12 11/23/2022
Xilio therapeutics announces pipeline and business updates and third quarter 2022 financial results 11/09/2022
Xilio therapeutics to present at cowen 6th annual ‘io next' summit 11/04/2022
Xilio therapeutics to present at guggenheim nantucket therapeutics conference 09/22/2022
Xilio therapeutics appoints tomas j. heyman to board of directors 09/15/2022
Xilio therapeutics to present at morgan stanley 20th annual global healthcare conference 09/06/2022
Xilio therapeutics announces encouraging preliminary phase 1 dose-escalation data for xtx101, a tumor-selective anti-ctla-4, and reports pipeline and business updates and second quarter 2022 financial results 08/09/2022
Xilio therapeutics announces promotion of martin huber, m.d., to president 06/16/2022
Xilio therapeutics to present at the h.c. wainwright global investment conference 05/18/2022
Xilio therapeutics reports pipeline and business highlights and first quarter 2022 financial results 05/12/2022
Xilio therapeutics to present at the 21st annual needham virtual healthcare conference 04/07/2022
Xilio therapeutics reports pipeline and business progress and fourth quarter and full year 2021 financial results 03/01/2022
Xilio therapeutics to participate in the cowen 42nd annual healthcare conference 02/28/2022
Xilio therapeutics to participate in the guggenheim 4th annual oncology day 02/03/2022
Xilio therapeutics announces initiation of patient dosing in phase 1/2 clinical trial of xtx202 for the treatment of patients with solid tumors 01/20/2022
Xilio therapeutics appoints yuan xu, ph.d., to its board of directors 01/06/2022
Xilio therapeutics reports pipeline and business progress and third quarter 2021 financial results 12/02/2021
Xilio therapeutics announces closing of initial public offering 10/26/2021
Xilio therapeutics announces pricing of initial public offering 10/21/2021

More Headlines

News
Xilio Therapeutics to Present at the Citi 2023 Virtual Oncology Leadership Summit WALTHAM, Mass., Feb. 16, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that René Russo, Pharm.D., chief executive officer, will participate in Citi's 2023 Virtual Oncology Leadership Summit on Thursday, February 23, 2023, at 9:00 a.m. ET. 02/16/2023
Xilio Therapeutics to Present at the Guggenheim Healthcare Talks Oncology Day WALTHAM, Mass., Feb. 02, 2023 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that René Russo, Pharm.D., chief executive officer, will participate in a fireside chat at the Guggenheim Healthcare Talks Oncology Day on Thursday, February 9, 2023, at 3:55 p.m. ET in New York. 02/02/2023
Xilio Therapeutics to Present at Cowen 6th Annual ‘IO Next' Summit WALTHAM, Mass., Nov. 04, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-activated immuno-oncology therapies for people living with cancer, today announced that the company will participate in a virtual fireside chat at the Cowen 6th Annual IO Next Summit on Friday, November 11, 2022, at 1:40 p.m. ET. 11/04/2022
Xilio Therapeutics to Present at Guggenheim Nantucket Therapeutics Conference WALTHAM, Mass., Sept. 22, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced that the company will participate in a fireside chat at the Guggenheim Nantucket Therapeutics Conference on Thursday, September 29, 2022, at 10:15 a.m. ET. 09/22/2022
Xilio Therapeutics to Present at Morgan Stanley 20th Annual Global Healthcare Conference WALTHAM, Mass., Sept. 06, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced that the company will participate virtually in a fireside chat at the Morgan Stanley 20th Annual Global Healthcare Conference on Tuesday, September 13, 2022, at 2:55 p.m. ET. 09/06/2022
Xilio Therapeutics to Present at the H.C. Wainwright Global Investment Conference WALTHAM, Mass., May 18, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced that Marty Huber, M.D., president of research and development and chief medical officer, will present at the H.C. Wainwright Global Investment Conference on Wednesday, May 25, 2022, at 2:30 p.m. ET. 05/18/2022
Xilio Therapeutics to Present at the 21st Annual Needham Virtual Healthcare Conference WALTHAM, Mass., April 07, 2022 (GLOBE NEWSWIRE) -- Xilio Therapeutics, Inc. (Nasdaq: XLO), a biotechnology company developing tumor-selective immuno-oncology therapies for people living with cancer, today announced that Marty Huber, M.D., president of research and development and chief medical officer, will present at the 21st Annual Needham Virtual Healthcare Conference on Thursday, April 14, 2022, at 8:00 a.m. ET. 04/07/2022
Xilio Therapeutics Seeks $125 Million In U.S. IPO Xilio Therapeutics has filed proposed terms for a $125 million IPO. The firm is developing immuno-oncology-based treatments for solid tumors and other cancer conditions. 10/18/2021

Unlock

XLO Ratings Summary

XLO Quant Ranking